Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] - 1 Feb 2024

Chen Peipei, Long Junyu, Zhang Jiayang, Xie Fucun, Wu Wei, Tian Zhuang, Zhang Shuyang, Yu Kang

Abstract excerpt

BACKGROUND: Janus kinase 2 (JAK2) mutation plays an important role in T cell immunity. However, the effect of JAK2 mutation on immunotherapy is largely uncharacterized. METHODS: In this study, we analyzed the effect of JAK2 mutation on the efficacy and outcomes of immune checkpoint inhibitor (ICI) therapy in the discovery cohort (n = 662) and the verification cohort (n = 1423). Furthermore, we explored the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Janus Kinase 2

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 38200372
DOI: 10.1007/s00011-023-01833-w
PMCID: PMC10824873

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.PMID 38200372Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironmentsSemantic proximity Read ↗

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.Semantic proximity Read ↗

Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity Read ↗

Landscape and functional impact of variants of unknown significance of immune response genes in human cancer.Semantic proximity Read ↗

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung CancerSemantic proximity Read ↗

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read ↗

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.Semantic proximity Read ↗

Landscape and functional impact of missense mutations of immune response genes in human cancerSemantic proximity Read ↗

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.